Evidence map›Paper›PMID 27030584›Full record

ArticleVirulence2016

Immunoglobulin G-dependent enhancement of the infection with Coxsackievirus B4 in a murine system.

Firas Elmastour, Hela Jaidane, Leila Aguech-Oueslati, Mehdi Ayech Benkahla, Mahjoub Aouni, Jawhar Gharbi, Famara Sane, Didier Hober

Open access · goldAbstract read
In one paragraph

Article in Virulence, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Firas Elmastoura Université de Lille; Faculté de Médecine, CHRU de Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Hela Jaidaneb Université de Monastir, Laboratoire des Maladies Transmissibles et Substances Biologiquement Actives LR99ES27, Faculté de Pharmacie de Monastir , Monastir , Tunisia.
Leila Aguech-Oueslatia Université de Lille; Faculté de Médecine, CHRU de Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Mehdi Ayech Benkahlaa Université de Lille; Faculté de Médecine, CHRU de Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Mahjoub Aounib Université de Monastir, Laboratoire des Maladies Transmissibles et Substances Biologiquement Actives LR99ES27, Faculté de Pharmacie de Monastir , Monastir , Tunisia.
Jawhar Gharbib Université de Monastir, Laboratoire des Maladies Transmissibles et Substances Biologiquement Actives LR99ES27, Faculté de Pharmacie de Monastir , Monastir , Tunisia.
Famara Sanea Université de Lille; Faculté de Médecine, CHRU de Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Didier Hobera Université de Lille; Faculté de Médecine, CHRU de Lille, Laboratoire de Virologie/EA3610 , Lille , France.
Tunis University · TNUniversité de Lille · FRUniversity of Monastir · TNCentre Hospitalier Universitaire de Lille · FRInstitut de Virologie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It was demonstrated that specific IgG can enhance the infection with CV-B4, in vitro, in the human system. This enhancement could be involved in the pathophysiology of CV-B4 induced diseases. To investigate further the role of enhancing IgG in the infection with CV-B4 E2 in vivo, animal models are needed. Therefore, it was decided to assess whether inoculation of CV-B4 E2 to mice results in the appearance of IgG able to enhance the infection with this virus. Swiss albino mice were inoculated with CV-B4 E2 intraperitoneally. Serum samples were obtained from tail vein blood collected from day 0 to day 80 p.i. IgG were isolated by Protein G affinity chromatography. Seroneutralisation assays were carried out. In total murine spleen cells cultures inoculated with CV-B4 E2 mixed with various dilutions of serum or IgG samples, the enhancing activity was assayed through i) the antiviral activity titer of supernatants ii) the detection of intracellular viral RNA by RT-PCR iii) the level of infectious particles in supernatants. In most serum samples (76/105), neutralizing and enhancing activities were detected peaking between days 14 and 30 p.i and were higher in sera from mice inoculated with 2.10(6) TCID50 units than with lower doses. The enhancing activity was due to the IgG-enriched fraction of serum from CV-B4 E2 infected animals but not from control animals. These data show that IgG from immune mice can enhance the infection of splenocytes with CV-B4 E2 in vitro and open the way to explore whether such an enhancing activity can play a role in vivo.

Indexed as

Antibody-Dependent EnhancementAnimalsAntibodies, NeutralizingCoxsackievirus InfectionsCulture MediaEnterovirus B, HumanImmunoglobulin GMiceNeutralization TestsRNA, ViralSpleenAntibodies, NeutralizingCulture MediaImmunoglobulin GRNA, Viralantiviral activityenteroviral RNAenterovirusin vitroserumspleen cells

Identifiers

PMID27030584
PMCPMC5026789
OpenAlexW2334501022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.